-Marketwatch, Feb. 8, 2023Galapagos ADRs Down 7% as Crohn's Study Misses Endpoints.
Galapagos NV American depositary receipts fell 7% to $40.45 in late trading after a Phase 3 trial of filgotinib for Crohn's disease didn't meet two co-primary endpoints. Galapagos said it decided not to submit a Marketing Authorization Application in Europe based on the data.
This is another JAK1 inhibitor that fails in clinical trials.
Be careful, there is a lot of money pushing these JAK1 inhibitors, but they can have serious side effects and are consistently ineffective to treat crohn's disease. Some of them have been blocked by the FDA on safety concerns.
Tofacitinib is another one of those JAK1 inhibitors, which also failed in trials.
There were no significant differences in the percentage of patients with moderate-to-severe active Crohn’s disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib (1, 5, or 15 mg) or placebo twice daily.